Otarmeni™ Gene Therapy Treatment Centers
ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions. Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Otarmeni** (lunsotogene parvec-cwha) which is approved to treat ***Otoferlin (OTOF)* gene-related hearing loss**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
Arizona	Phoenix	Phoenix Children's Hospital
California	San Diego	Rady Children's Hospital San Diego
	San Francisco	U.C.S.F. Medical Center
Ohio	Cincinnati	Cincinnati Children's Hospital Medical Center
Wisconsin	Milwaukee	Children's Hospital of Wisconsin

© 2026 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11796. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or clientservices@emergingtherapies.com. Please note that coverage for any indicated services is subject to applicable plan documents. 11/10/2026